North Carolina is currently home to 2641 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Preventing Type 2 Diabetes in Black Emergent Adult
NCT06848244
Recruiting
Black Americans are disproportionately affected by diabetes, with nearly double the rates of type 2 diabetes mellitus (T2DM), compared to non-Hispanic White adults. Though numerous factors affect these disparities, one modifiable risk factor may be that of binge eating (BE), which increases risk for binge-eating disorder (BED), which is associated with severe obesity, and often precedes a T2DM diagnosis, beginning in childhood or adolescence. Nearly 30% of Black women with obesity report binge e... Read More
Gender:
FEMALE
Ages:
Between 18 years and 25 years
Trial Updated:
07/28/2025
Locations: UNC-Chapel Hill, Chapel Hill, North Carolina
Conditions: Type 2 Diabetes Mellitus, Binge-Eating Disorder, Binge Eating, Obesity
Register for Updates
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06799000
Recruiting
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/28/2025
Locations: OnSite Clinical Solutions LLC, Huntersville, North Carolina
Conditions: Hidradenitis Suppurativa
Register for Updates
A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)
NCT06602453
Recruiting
The aim of this study is to evaluate the efficacy and safety of GDC-8264 compared with placebo in participants undergoing cardiac surgery who are determined to be at moderate to high risk of developing AKI and subsequent MAKE at 90 days after surgery (MAKE90). The study will be performed in two parts- Part 1 and Part 2.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/28/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Acute Kidney Injury
Register for Updates
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986
Recruiting
This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC).
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
07/28/2025
Locations: Digestive Health Partners, PA, Asheville, North Carolina
Conditions: Moderately to Severely Active Ulcerative Colitis
Register for Updates
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855
Recruiting
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC).
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
07/28/2025
Locations: Charlotte Gastroenterology and Hepatology, P.L.L.C, Charlotte, North Carolina
Conditions: Moderately to Severely Active Ulcerative Colitis
Register for Updates
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/28/2025
Locations: Akero Clinical Study Site, Chapel Hill, North Carolina
Conditions: NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Register for Updates
Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
NCT06517641
Recruiting
BMT CTN 2207 will investigate the use of marrow transplantation for treatment of severe aplastic anemia that has not previously been treated.
Gender:
ALL
Ages:
Between 3 years and 75 years
Trial Updated:
07/28/2025
Locations: UNC Chapel Hill, Chapel Hill, North Carolina
Conditions: Severe Aplastic Anemia
Register for Updates
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
NCT06496178
Recruiting
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Site 98, Chapel Hill, North Carolina
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
NCT06470451
Recruiting
To evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Accellacare (PMG), Wilmington, North Carolina
Conditions: CTCL/ Mycosis Fungoides, CTCL, Mycosis Fungoides, Cutaneous T Cell Lymphoma
Register for Updates
ADVENT Post Approval Study
NCT06431815
Recruiting
The ADVENT Post Approval Study (PAS) is a prospective, global, multicenter, observational study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: East Carolina University Medical Center, Greenville, North Carolina
Conditions: Paroxysmal Atrial Fibrillation
Register for Updates
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
NCT06411249
Recruiting
This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ongoing disease activity despite stable initial SLE therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: GSK Investigational Site, Charlotte, North Carolina
Conditions: Systemic Lupus Erythematosus
Register for Updates
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
NCT06176261
Recruiting
The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the study drug used in this research study is: Datopotamab deruxtecan (a type of antibody-drug conjugate)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Breast Cancer, Breast Cancer Female, Metastatic Triple-Negative Breast Carcinoma, ER Positive Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER-negative Breast Cancer
Register for Updates